| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2022 | 868.52% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
| 07/15/2022 | 81.6% | Morgan Stanley | $2 → $0.75 | Maintains | Underweight |
| 06/02/2022 | 747.46% | Laidlaw & Co. | → $3.5 | Initiates Coverage On | → Buy |
| 05/25/2022 | 384.26% | Piper Sandler | $30 → $2 | Maintains | Overweight |
| 05/11/2022 | 384.26% | Morgan Stanley | $8.55 → $2 | Maintains | Underweight |
| 05/10/2022 | 1970.22% | Morgan Stanley | $0.57 → $8.55 | Maintains | Underweight |
| 04/12/2022 | 38.01% | Morgan Stanley | $0.53 → $0.57 | Maintains | Underweight |
| 03/04/2022 | 28.33% | Morgan Stanley | $0.5 → $0.53 | Maintains | Underweight |
| 11/16/2021 | 384.26% | HC Wainwright & Co. | $2.5 → $2 | Maintains | Buy |
| 10/21/2021 | 505.33% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
| 10/14/2021 | 93.7% | Morgan Stanley | → $0.8 | Downgrades | Equal-Weight → Underweight |
| 08/12/2021 | 142.13% | Morgan Stanley | $3 → $1 | Maintains | Equal-Weight |
| 06/07/2021 | 868.52% | HC Wainwright & Co. | $7 → $4 | Maintains | Buy |
| 03/08/2021 | 1594.92% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 10/02/2020 | 1110.65% | Stifel | → $5 | Initiates Coverage On | → Buy |
| 08/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 06/09/2020 | 2079.18% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 06/08/2020 | 2563.44% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 05/27/2020 | 5953.27% | Oppenheimer | $23 → $25 | Maintains | Outperform |
| 12/11/2019 | 2563.44% | HC Wainwright & Co. | $9 → $11 | Reiterates | → Buy |
| 10/16/2019 | 2079.18% | Cantor Fitzgerald | → $9 | Assumes | → Overweight |
| 09/26/2018 | 2079.18% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 06/27/2018 | 1837.05% | RBC Capital | → $8 | Initiates Coverage On | → Outperform |
| 06/18/2018 | 2079.18% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 03/19/2018 | 3531.96% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
Evofem Biosciences Questions & Answers
The latest price target for Evofem Biosciences (OTCPK: EVFM) was reported by HC Wainwright & Co. on August 15, 2022. The analyst firm set a price target for $4.00 expecting EVFM to rise to within 12 months (a possible 868.52% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Evofem Biosciences (OTCPK: EVFM) was provided by HC Wainwright & Co., and Evofem Biosciences maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evofem Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evofem Biosciences was filed on August 15, 2022 so you should expect the next rating to be made available sometime around August 15, 2023.
While ratings are subjective and will change, the latest Evofem Biosciences (EVFM) rating was a maintained with a price target of $2.00 to $4.00. The current price Evofem Biosciences (EVFM) is trading at is $0.41, which is out of the analyst's predicted range.